Open AccessCoeliac disease screening in children: assessment of a novel anti‐gliadin antibody assay
Author(s) -
Leach Steven T.,
Aurangzeb Brekhna,
Day Andrew S.
Publication year - 2008
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.20263
Subject(s) - tissue transglutaminase , medicine , gliadin , coeliac disease , etiology , disease , immunology , screening test , antibody , gastroenterology , pediatrics , gluten , pathology , biology , biochemistry , enzyme
Coeliac disease (CD) screening has progressed rapidly with tissue transglutaminase (TTG), the screening tool of choice. However, TTG may be unreliable in young children and advances in CD etiology understanding have seen improvements in anti‐gliadin (AGA) assay technology. The aim of this study was to investigate the utility of an updated and refined AGA (Neogliadin) assay for CD screening in children with gastrointestinal symptoms. Children attending the Sydney Children's Hospital, Randwick, with gastrointestinal symptoms had sera collected and assayed by Neogliadin and commercial TTG assays in addition to the usual clinical work‐up. One hundred and fifteen children were recruited in which 32 were diagnosed with CD. AGA–IgA screening by Neogliadin showed improved sensitivity (83%) and specificity (91%) but did not eclipse the sensitivity (93%) and specificity (90%) of TTG–IgA screening. In the children diagnosed with CD, 7 were identified as younger than 5 years of age with 4/7 AGA–IgA positive, 5/7 AGA–IgG positive, and 6/7 TTG–IgA positive. The updated Neogliadin IgA assay does not improve on the accuracy achieved by TTG screening. TTG appears to be a suitable screening tool for children younger than 5 years of age although this preliminary finding requires confirmation. J. Clin. Lab. Anal. 22:327–333, 2008. © 2008 Wiley‐Liss, Inc.